Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 August, 2019 02:27 IST
Sun Pharma announces availability of ILUMYA in United States
Source: IRIS | 24 Oct, 2018, 10.22AM
Comments  |  Post Comment

Sun Pharmaceutical Industries announced that moderate-to-severe psoriasis treatment ILUMYATM (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYATM is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.

''The availability of ILUMYATM is an important milestone for Sun Pharma (Q,N,C,F)* as we expand our specialty medicine portfolio in the U.S. ILUMYATM offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis,'' said Abhay Gandhi, Chief Executive Officer, Sun Pharma, North America. ''We understand the importance of patient and physician choice, and are committed to making ILUMYATM among the most cost-effective treatments on the market.''

Shares of the company declined Rs 9.5, or 1.65%, to trade at Rs 566.80. The total volume of shares traded was 105,402 at the BSE (10.12 a.m., Wednesday).

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer